Zura Bio Ltd (ZURA) concluded trading on Thursday at a closing price of $1.76, with 3.39 million shares of worth about $5.97 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -52.82% during that period and on January 30, 2025 the price saw a gain of about 1.73%. Currently the company’s common shares owned by public are about 65.29M shares, out of which, 47.09M shares are available for trading.
Stock saw a price change of 2.33% in past 5 days and over the past one month there was a price change of -29.60%. Year-to-date (YTD), ZURA shares are showing a performance of -29.60% which decreased to -47.15% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.60 but also hit the highest price of $6.35 during that period. The average intraday trading volume for Zura Bio Ltd shares is 478.55K. The stock is currently trading -11.79% below its 20-day simple moving average (SMA20), while that difference is down -27.16% for SMA50 and it goes to -51.94% lower than SMA200.
Zura Bio Ltd (NASDAQ: ZURA) currently have 65.29M outstanding shares and institutions hold larger chunk of about 53.63% of that.
The stock has a current market capitalization of $114.92M and its 3Y-monthly beta is at -0.02. It has posted earnings per share of -$0.59 in the same period. It has Quick Ratio of 10.36 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ZURA, volatility over the week remained 8.68% while standing at 8.74% over the month.
Stock’s fiscal year EPS is expected to rise by 68.12% while it is estimated to decrease by -11.07% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on November 04, 2024 offering an Outperform rating for the stock and assigned a target price of $15 to it. Coverage by H.C. Wainwright stated Zura Bio Ltd (ZURA) stock as a Neutral in their note to investors on September 05, 2024, suggesting a price target of $5 for the stock. On May 03, 2024, Piper Sandler Initiated their recommendations, while on October 10, 2023, Ladenburg Thalmann Initiated their ratings for the stock with a price target of $10. Stock get an Outperform rating from Oppenheimer on August 25, 2023.
